Literature DB >> 33666780

Disease Presentation, Treatment Options, and Outcomes for Myeloid Immunodeficiencies.

Elizabeth M Kang1.   

Abstract

PURPOSE OF REVIEW: Up-to-date review on various types of immunodeficiencies with a significant myeloid component including some more recently described congenital disorders. RECENT
FINDINGS: While a number of disorders have been described in the past, genetic sequencing has led to the identification of the specific disorders and clarified their pathophysiology. Advances in genetic therapies including genetic editing should provide future treatments beyond hematopoietic stem cell transplant for patients with these rare disorders. Neutrophils (or granulocytes) are a major contributor to infection surveillance and clearance, and defective neutrophils characteristically lead to pyogenic infections. Deficiency in numbers, either iatrogenic or congenital; functional defects; and/or inability to target to the sites of infection can all lead to serious morbidity and mortality; however, myeloid-based immunodeficiencies are not all the same. Having absent neutrophils, that is, neutropenia, has implications different to those of having dysfunctional neutrophils as will become evident as the various disorders are reviewed.

Entities:  

Keywords:  Gene therapy; Immunodeficiencies; Myeloid defects; Transplantation

Mesh:

Year:  2021        PMID: 33666780      PMCID: PMC8162003          DOI: 10.1007/s11882-020-00984-8

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  117 in total

1.  Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy.

Authors:  Philip S Rosenberg; Cornelia Zeidler; Audrey A Bolyard; Blanche P Alter; Mary A Bonilla; Laurence A Boxer; Yigal Dror; Sally Kinsey; Daniel C Link; Peter E Newburger; Akiko Shimamura; Karl Welte; David C Dale
Journal:  Br J Haematol       Date:  2010-04-29       Impact factor: 6.998

2.  Wiskott-Aldrich syndrome protein is necessary for efficient IgG-mediated phagocytosis.

Authors:  R Lorenzi; P M Brickell; D R Katz; C Kinnon; A J Thrasher
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

Review 3.  An update on the diagnosis and treatment of chronic idiopathic neutropenia.

Authors:  David C Dale; Audrey A Bolyard
Journal:  Curr Opin Hematol       Date:  2017-01       Impact factor: 3.284

4.  Corticosteroids in the treatment of severe nocardia pneumonia in chronic granulomatous disease.

Authors:  Alexandra F Freeman; Beatriz E Marciano; Victoria L Anderson; Gulbu Uzel; Christ Costas; Steven M Holland
Journal:  Pediatr Infect Dis J       Date:  2011-09       Impact factor: 2.129

5.  Common severe infections in chronic granulomatous disease.

Authors:  Beatriz E Marciano; Christine Spalding; Alan Fitzgerald; Daphne Mann; Thomas Brown; Sharon Osgood; Lynne Yockey; Dirk N Darnell; Lisa Barnhart; Janine Daub; Lisa Boris; Amy P Rump; Victoria L Anderson; Carissa Haney; Douglas B Kuhns; Sergio D Rosenzweig; Corin Kelly; Adrian Zelazny; Tamika Mason; Suk See DeRavin; Elizabeth Kang; John I Gallin; Harry L Malech; Kenneth N Olivier; Gulbu Uzel; Alexandra F Freeman; Theo Heller; Christa S Zerbe; Steven M Holland
Journal:  Clin Infect Dis       Date:  2014-12-23       Impact factor: 9.079

Review 6.  Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: advances in biology and future directions for treatment.

Authors:  Sung-Yun Pai; Luigi D Notarangelo
Journal:  Immunol Allergy Clin North Am       Date:  2010-05       Impact factor: 3.479

7.  Long-term follow-up of foamy viral vector-mediated gene therapy for canine leukocyte adhesion deficiency.

Authors:  Thomas R Bauer; Laura M Tuschong; Katherine R Calvo; Heather R Shive; Tanya H Burkholder; Eleanor K Karlsson; Robert R West; David W Russell; Dennis D Hickstein
Journal:  Mol Ther       Date:  2013-03-26       Impact factor: 11.454

8.  Long-term interferon-gamma therapy for patients with chronic granulomatous disease.

Authors:  Beatriz E Marciano; Robert Wesley; Ellen S De Carlo; Victoria L Anderson; Lisa A Barnhart; Dirk Darnell; Harry L Malech; John I Gallin; Steven M Holland
Journal:  Clin Infect Dis       Date:  2004-08-16       Impact factor: 9.079

9.  Bone-marrow transplantation for inborn error of phagocytic cells associated with defective adherence, chemotaxis, and oxidative response during opsonised particle phagocytosis.

Authors:  A Fischer; P H Trung; B Descamps-Latscha; B Lisowska-Grospierre; I Gerota; N Perez; C Scheinmetzler; A Durandy; J L Virelizier; C Griscelli
Journal:  Lancet       Date:  1983-08-27       Impact factor: 79.321

Review 10.  Neutrophil specific granule deficiency.

Authors:  J I Gallin
Journal:  Annu Rev Med       Date:  1985       Impact factor: 13.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.